The effect of the stereoisomers of butaclamol on neurotensin content in discrete regions of the rat brain. 1988

G Bissette, and W T Dauer, and C D Kilts, and L O'Connor, and C B Nemeroff
Department of Psychiatry, Duke University Medical Center, Durham, North Carolina 27710.

The prevailing hypothesis concerning the mechanism of antipsychotic drug action is principally based on the striking correlation between their clinical potency and their potency in blockade of D2 dopamine receptors. However, most of these compounds also have effects at serotonin, acetylcholine, histamine, and alpha-adrenergic receptors and have recently been shown to alter the concentrations of certain neuropeptides in the rat brain after chronic drug administration. One such neuropeptide that is increased in concentration in dopamine terminal regions by clinically effective neuroleptic drugs is neurotensin (NT). Neurotensin is closely associated with dopamine neurons, as demonstrated by evidence derived from anatomic, physiologic, and pharmacologic studies. In this report, we determined the effects of chronic administration of the potent D2 receptor antagonist (+)-butaclamol and its inactive (-) stereoisomer on regional brain NT content. Moreover, we sought to determine whether the effects of haloperidol on NT concentrations can be antagonized by concomitant administration of an indirect dopamine agonist, d-amphetamine. Neurotensin content in the caudate nucleus and nucleus accumbens of the rat were significantly increased by 3 weeks of daily injections of haloperidol or (+)-butaclamol, but not (-)-butaclamol. d-Amphetamine did not alter this effect of haloperidol on NT concentrations in either the nucleus accumbens or caudate nucleus. These data are concordant with the hypothesis that D2 receptor blockade is required for NT concentration increases after antipsychotic drug treatment and that the increase in synaptic cleft dopamine content produced by d-amphetamine cannot reverse this effect of dopamine receptor antagonists.

UI MeSH Term Description Entries
D008297 Male Males
D009496 Neurotensin A biologically active tridecapeptide isolated from the hypothalamus. It has been shown to induce hypotension in the rat, to stimulate contraction of guinea pig ileum and rat uterus, and to cause relaxation of rat duodenum. There is also evidence that it acts as both a peripheral and a central nervous system neurotransmitter.
D009928 Organ Specificity Characteristic restricted to a particular organ of the body, such as a cell type, metabolic response or expression of a particular protein or antigen. Tissue Specificity,Organ Specificities,Specificities, Organ,Specificities, Tissue,Specificity, Organ,Specificity, Tissue,Tissue Specificities
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002069 Butaclamol A benzocycloheptapyridoisoquinolinol that has been used as an antipsychotic, especially in schizophrenia. AY-23,028,Butaclamol Hydrochloride,AY 23,028,AY23,028,Hydrochloride, Butaclamol
D003913 Dextroamphetamine The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic. d-Amphetamine,Curban,Dexamfetamine,Dexamphetamine,Dexedrine,Dextro-Amphetamine Sulfate,DextroStat,Dextroamphetamine Sulfate,Oxydess,d-Amphetamine Sulfate,dextro-Amphetamine,Dextro Amphetamine Sulfate,Sulfate, Dextroamphetamine,d Amphetamine,d Amphetamine Sulfate,dextro Amphetamine
D003986 Dibenzocycloheptenes A family of tricyclic hydrocarbons whose members include many of the commonly used tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC).
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol

Related Publications

G Bissette, and W T Dauer, and C D Kilts, and L O'Connor, and C B Nemeroff
May 1987, The Journal of pharmacology and experimental therapeutics,
G Bissette, and W T Dauer, and C D Kilts, and L O'Connor, and C B Nemeroff
April 1975, Journal of neurochemistry,
G Bissette, and W T Dauer, and C D Kilts, and L O'Connor, and C B Nemeroff
December 2011, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
G Bissette, and W T Dauer, and C D Kilts, and L O'Connor, and C B Nemeroff
October 1979, Neuroscience letters,
G Bissette, and W T Dauer, and C D Kilts, and L O'Connor, and C B Nemeroff
October 1984, Biulleten' eksperimental'noi biologii i meditsiny,
G Bissette, and W T Dauer, and C D Kilts, and L O'Connor, and C B Nemeroff
November 1974, Biochemical pharmacology,
G Bissette, and W T Dauer, and C D Kilts, and L O'Connor, and C B Nemeroff
January 1981, Neurobiology of aging,
G Bissette, and W T Dauer, and C D Kilts, and L O'Connor, and C B Nemeroff
March 1986, Journal of neurochemistry,
G Bissette, and W T Dauer, and C D Kilts, and L O'Connor, and C B Nemeroff
October 1999, Brain research,
G Bissette, and W T Dauer, and C D Kilts, and L O'Connor, and C B Nemeroff
May 1993, Biopharmaceutics & drug disposition,
Copied contents to your clipboard!